|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD, Fedewa SA, Ahnen DJ,
Meester RGS, Barzi A and Jemal A: Colorectal cancer statistics,
2017. CA Cancer J Clin. 67:177–193. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fearon ER and Vogelstein B: A genetic
model for colorectal tumorigenesis. Cell. 61:759–767. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vincent MD: Cancer: Beyond speciation. Adv
Cancer Res. 112:283–350. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Terzić J, Grivennikov S, Karin E and Karin
M: Inflammation and colon cancer. Gastroenterology. 138:2101–2114.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yokoyama Y, Watanabe T, Tamura Y,
Hashizume Y, Miyazono K and Ehata S: Autocrine BMP-4 signaling is a
therapeutic target in colorectal cancer. Cancer Res. 77:4026–4038.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Miyazono K, Kamiya Y and Morikawa M: Bone
morphogenetic protein receptors and signal transduction. J Biochem.
147:35–51. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang Y, Chen X, Qiao M, Zhang BQ, Wang N,
Zhang Z, Liao Z, Zeng L, Deng Y, Deng F, et al: Bone morphogenetic
protein 2 inhibits the proliferation and growth of human colorectal
cancer cells. Oncol Rep. 32:1013–1020. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen D, Zhao M, Harris SE and Mi Z: Signal
transduction and biological functions of bone morphogenetic
proteins. Front Biosci. 9:349–358. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Celeste AJ: Bone morphogenetic protein-9,
a new member of the TGF-β superfamily. J Bone Miner Res. 1(9):
S1361994.
|
|
11
|
Wagner DO, Sieber C, Bhushan R, Börgermann
JH, Graf D and Knaus P: BMPs: From bone to body morphogenetic
proteins. Sci Signal. 3:mr12010.PubMed/NCBI
|
|
12
|
Plouhinec JL, Zakin L and De Robertis EM:
Systems control of BMP morphogen flow in vertebrate embryos. Curr
Opin Genet Dev. 21:696–703. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Reddi AH and Reddi A: Bone morphogenetic
proteins (BMPs): From morphogens to metabologens. Cytokine Growth
Factor Rev. 20:341–342. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ploemacher RE, Engels LJ, Mayen AE, Thies
S and Neben S: Bone morphogenetic protein 9 is a potent synergistic
factor for murine hemopoietic progenitor cell generation and colony
formation in serum-free cultures. Leukemia. 13:428–437. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Helm GA, Alden TD, Beres EJ, Hudson SB,
Das S, Engh JA, Pittman DD, Kerns KM and Kallmes DF: Use of bone
morphogenetic protein-9 gene therapy to induce spinal arthrodesis
in the rodent. J Neurosurg. 92 (Suppl):S191–S196. 2000.
|
|
16
|
Lopez-Coviella I, Berse B, Krauss R, Thies
RS and Blusztajn JK: Induction and maintenance of the neuronal
cholinergic phenotype in the central nervous system by BMP-9.
Science. 28:313–316. 2000. View Article : Google Scholar
|
|
17
|
Chen C, Grzegorzewski KJ, Barash S, Zhao
Q, Schneider H, Wang Q, Singh M, Pukac L, Bell AC, Duan R, et al:
An integrated functionalgenomics screening program reveals a role
for BMP-9 in glucose homeostasis. Nat Biotechnol. 21:294–301. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Truksa J, Peng HF, Lee P and Beutler E:
Bone morphogenetic proteins 2, 4, and 9 stimulate murine hepcidin 1
expression independently of Hfe, transferrin receptor 2 (Tfr2), and
IL-6. Proc Natl Acad Sci USA. 103:10289–10293. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
David L, Mallet C, Mazerbourg S, Feige JJ
and Bailly S: Identification of BMP9 and BMP10 as functional
activators of the orphan activin receptor-like kinase 1 (ALK1) in
endothelial cells. Blood. 109:1953–1961. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Na KY, Kim HS, Lee SK, Jung WW, Sung JY,
Kim YW and Park YK: Papillary thyroid carcinoma with bone
formation. Pathol Res Pract. 209:14–18. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Herrera B, van Dinther M, Ten Dijke P and
Inman GJ: Autocrine bone morphogenetic protein-9 signals through
activin receptor-like kinase-2/Smad1/Smad4 to promote ovarian
cancer cell proliferation. Cancer Res. 69:9254–9262. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Herrera B, García-Álvaro M, Cruz S, Walsh
P, Fernández M, Roncero C, Fabregat I, Sánchez A and Inman GJ: BMP9
is a proliferative and survival factor for human hepatocellular
carcinoma cells. PLoS One. 8:e695352013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li Q, Gu X, Weng H, Ghafoory S, Liu Y,
Feng T, Dzieran J, Li L, Ilkavets I and Kruithof-de Julio M: Bone
morphogenetic protein-9 induces epithelial to mesenchymal
transition in hepatocellular carcinoma cells. Cancer Sci.
104:398–408. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ye L, Kynaston H and Jiang WG: Bone
morphogenetic protein-9 induces apoptosis in prostate cancer cells,
the role of prostate apoptosis response-4. Mol Cancer Res.
6:1594–1606. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Olsen OE, Wader KF, Misund K, Våtsveen TK,
Rø TB, Mylin AK, Turesson I, Størdal BF, Moen SH, Standal T, et al:
Bone morphogenetic protein-9 suppresses growth of myeloma cells by
signaling through ALK2 but is inhibited by endoglin. Blood Cancer
J. 4:e1962014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wan S, Liu Y, Weng Y, Wang W, Ren W, Fei
C, Chen Y, Zhang Z, Wang T, Wang J, et al: BMP9 regulates
cross-talk between breast cancer cells and bone marrow-derived
mesenchymal stem cells. Cell Oncol (Dordr). 37:363–375. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ren W, Liu Y, Wan S, Fei C, Wang W, Chen
Y, Zhang Z, Wang T, Wang J, Zhou L, et al: BMP9 inhibits
proliferation and metastasis of HER2-positive SK-BR-3 breast cancer
cells through ERK1/2 and PI3K/AKT pathways. PLoS One. 9:e968162014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ren W, Sun X, Wang K, Feng H, Liu Y, Fei
C, Wan S, Wang W, Luo J, Shi Q, et al: BMP9 inhibits the bone
metastasis of breast cancer cells by downregulating CCN2
(connective tissue growth factor, CTGF) expression. Mol Biol Rep.
41:1373–1383. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
America Joint Committee on Cancer, . The
7th edition of the AJCC cancer staging manual. 7th. New York:
Springer; 2010
|
|
30
|
Edge SB and Compton CC: The American joint
committee on cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sarma DP: Dukes' classification of rectal
cancer. South Med J. 81:407–408. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kurashina K, Yamashita Y, Ueno T, Koinuma
K, Ohashi J, Horie H, Miyakura Y, Hamada T, Haruta H, Hatanaka H,
et al: Chromosome copy number analysis in screening for prognosis-
related genomic regions in colorectal carcinoma. Cancer Sci.
99:1835–1840. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gaedcke J, Grade M, Jung K, Camps J, Jo P,
Emons G, Gehoff A, Sax U, Schirmer M, Becker H, et al: Mutated KRAS
results in overexpression of DUSP4, a MAP-kinase phosphatase, and
SMYD3, a histone methyltransferase, in rectal carcinomas. Genes
Chromosomes Cancer. 49:1024–1034. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Muto T, Bussey HJ and Morson BC: The
evolution of cancer of the colon and rectum. Cancer. 36:2251–2270.
1975. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kinzler KW and Vogelstein B: Lessons from
hereditary colorectal cancer. Cell. 87:159–170. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Herrera B, Dooley S and Breitkopf-Heinlein
K: Potential roles of bone morphogenetic protein (BMP)-9 in human
liver diseases. Int J Mol Sci. 15:5199–5220. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Astrologo L, Zoni E, Karkampouna S, Gray
PC, Klima I, Grosjean J, Goumans MJ, Hawinkels LJAC, van der Pluijm
G, Spahn M, et al: ALK1Fc Suppresses the human prostate cancer
growth in in vitro and in vivo preclinical models. Front Cell Dev
Biol. 5:1042017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lv Z, Yang D, Li J, Hu M, Luo M, Zhan X,
Song P, Liu C, Bai H, Li B, et al: Bone morphogenetic protein 9
overexpression reduces osteosarcoma cell migration and invasion.
Mol Cells. 36:119–126. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hardwick JC, Kodach LL, Offerhaus GJ and
van den Brink GR: Bone morphogenetic protein signalling in
colorectal cancer. Nat Rev Cancer. 8:806–812. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Allaire JM, Roy SA, Ouellet C, Lemieux É,
Jones C, Paquet M, Boudreau F and Perreault N: Bmp signaling in
colonic mesenchyme regulates stromal microenvironment and protects
from polyposis initiation. Int J Cancer. 138:2700–2712. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Voorneveld PW, Kodach LL, Jacobs RJ, van
Noesel CJ, Peppelenbosch MP, Korkmaz KS, Molendijk I, Dekker E,
Morreau H, van Pelt GW, et al: The BMP pathway either enhances or
inhibits the Wnt pathway depending on the SMAD4 and p53 status in
CRC. Br J Cancer. 112:122–130. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Howe JR, Bair JL, Sayed MG, Anderson ME,
Mitros FA, Petersen GM, Velculescu VE, Traverso G and Vogelstein B:
Germline mutations of the gene encoding bone morphogenetic protein
receptor 1A in juvenile polyposis. Nat Genet. 28:184–187. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Davis H, Raja E, Miyazono K, Tsubakihara Y
and Moustakas A: Mechanisms of action of bone morphogenetic
proteins in cancer. Cytokine Growth Factor Rev. 27:81–92. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Loh K, Chia JA, Greco S, Cozzi SJ,
Buttenshaw RL, Bond CE, Simms LA, Pike T, Young JP, Jass JR, et al:
Bone morphogenetic protein 3 inactivation is an early and frequent
event in colorectal cancer development. Genes Chromosomes Cancer.
47:449–460. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Yuan SX, Wang DX, Wu QX, Ren CM, Li Y,
Chen QZ, Zeng YH, Shao Y, Yang JQ, Bai Y, et al: BMP9/p38 MAPK is
essential for the antiproliferative effect of resveratrol on human
colon cancer. Oncol Rep. 35:939–947. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lorente-Trigos A, Varnat F, Melotti A,
Ruiz I and Altaba A: BMP signaling promotes the growth of primary
human colon carcinomas in vivo. J Mol Cell Biol. 2:318–332. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Sanjuan X, Fernández PL, Castells A,
Castronovo V, van den Brule F, Liu FT, Cardesa A and Campo E:
Differential expression of galectin 3 and galectin 1 in colorectal
cancer progression. Gastroenterology. 113:1906–1915. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Miyata Y, Watanabe S, Sagara Y, Mitsunari
K, Matsuo T, Ohba K and Sakai H: High expression of HuR in
cytoplasm, but not nuclei, is associated with malignant
aggressiveness and prognosis in bladder cancer. PLoS One.
8:e590952013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Steinke-Lange V and Holinski-Feder E:
Genetic screening and personalized prevention in colorectal cancer.
Visc Med. 35:226–230. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
De Roock W, De Vriendt V, Normanno N,
Ciardiello F and Tejpar S: KRAS, BRAF, PIK3CA, and PTEN mutations:
Implications for targeted therapies in metastatic colorectal
cancer. Lancet Oncol. 12:594–603. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Yoshimatsu Y, Lee YG, Akatsu Y, Taguchi L,
Suzuki HI, Cunha SI, Maruyama K, Suzuki Y, Yamazaki T, Katsura A,
et al: Bone morphogenetic protein-9 inhibits lymphatic vessel
formation via activin receptor-like kinase 1 during development and
cancer progression. Proc Natl Acad Sci USA. 110:18940–18945. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Cunha SI and Pietras K: ALK1 as an
emerging target for antiangiogenic therapy of cancer. Blood.
117:6999–7006. 2011. View Article : Google Scholar : PubMed/NCBI
|
